Banca de DEFESA: YVES MARTINS VARELA

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
DISCENTE : YVES MARTINS VARELA
DATA : 30/08/2019
HORA: 14:00
LOCAL: Sala Sagui
TÍTULO:

Group Cognitive-Behavioral Therapy in the Treatment of Major Depressive Disorder

PALAVRAS-CHAVES:

Biomarker; Cortisol; Self esteem; Anxiety; Sleep.

PÁGINAS: 26
GRANDE ÁREA: Ciências Humanas
ÁREA: Psicologia
RESUMO:

Major Depressive Disorder (MDD) is a mental disorder whose prevalence grows significantly with each generation, today affects more than 320 million people and is predicted that by 2030 it will be the first disabling cause for work. To elucidate the neurobiology underlying MDD is useful to understand this disorder , and is a service to the advancement of clinical practice focused on its identification and treatment. In this context, there are psychophysiological parameters with potential to be biomarkers of MDD, including cortisol and the sleep quality. Likewise, it is understood that, besides depressive symptoms, other psychological aspects are linked to the presence and course of MDD, being anxiety and self-esteem some of the main ones. Thus , this study, a clinical trial, aimed evaluating before and after monotherapy treatment using group Cognitive Behavioral Therapy( GCBT), cortisol (plasma and salivary) levels , anxious symptoms, self-esteem levels and sleep quality in depressed patients (n = 20; women n = 11), specifically college students. Prior to treatment, patients showed higher plasma cortisol levels than their healthy peers, the control group (n = 25; women n = 13), and higher salivary cortisol response on awakening and poor sleep quality. Patients responded to the intervention with decreased of depressive symptoms, and 55% of the m achieved remission. In addition, there was a reduction in anxious symptoms, increased of self-esteem and improved sleep quality; however, cortisol levels remained without significant variations. Still, it was noticed that self-esteem had a mediating effect and that cortisol had a moderating effect on the symptoms of depression, due to the remission of MDD. In view of these data, the efficacy of GCBT monotherapy in the treatment of patients with mild and moderate levels of MDD was observed, which surpassed remission rates of clinical trials with psychotherapy, pharmacotherapy, and combined use of both. Therefore, it is understood be relevant additional studies that investigate the GCBT and psychophysiological biomarkers in order to contribute to the solidification of precision psychiatry.

MEMBROS DA BANCA:
Presidente - 1718518 - NICOLE LEITE GALVAO COELHO
Interna - 1350337 - FIVIA DE ARAUJO LOPES
Externa à Instituição - Melyssa Kellyane Cavalcanti Galdino - UFPB